Cost–effectiveness of Medicare’s coverage of immunosuppression medications for kidney transplant recipients
- 1 October 2009
- journal article
- review article
- Published by Informa UK Limited in Expert Review of Pharmacoeconomics & Outcomes Research
- Vol. 9 (5), 435-444
- https://doi.org/10.1586/erp.09.52
Abstract
Kidney transplantation is the preferred method of treating patients with end-stage renal disease. Transplantation improves the quality of life of the transplant recipient and also results in reduced treatment costs owing to the cost difference between dialysis and the post-transplant immunosuppression medications. Currently, the USA's Medicare program covers immunosuppression medications for 3 years post-transplant for nonelderly, nondisabled patients, and there is currently a proposal to extend this coverage from 3 years to a lifetime for all transplant recipients. Upon expiration of the current 3-year benefit, some patients are unable to afford to pay for the medication on their own, resulting in graft loss and a return to dialysis. This article reviews studies that documented the improvements in long-term transplant outcomes attributable to previous coverage extensions of immunosuppression medications, from both 1-3 years post-transplant for all transplant recipients in 1993 and the coverage extension from 3 years to lifetime for elderly and disabled patients in the year 2000. In addition, previous studies of the potential cost-effectiveness of a lifetime immunosuppression benefit for all patients are discussed.Keywords
This publication has 12 references indexed in Scilit:
- The cost-effectiveness of induction immunosuppression in kidney transplantationNephrology Dialysis Transplantation, 2009
- Income-Related Disparities in Kidney Transplant Graft Failures Are Eliminated by Medicare’s Immunosuppression CoverageAmerican Journal of Transplantation, 2008
- The financial impact of immunosuppressant expenses on new kidney transplant recipients*,†Clinical Transplantation, 2008
- Cost-Effectiveness of Extending Medicare Coverage of Immunosuppressive Medications to the Life of a Kidney TransplantAmerican Journal of Transplantation, 2004
- Income Inequality in the United States, 1913-1998The Quarterly Journal of Economics, 2003
- Effect of Extended Coverage of Immunosuppressive Medications by Medicare on the Survival of Cadaveric Renal TransplantsAmerican Journal of Transplantation, 2001
- Payment for Immunosuppression After Organ TransplantationPublished by American Medical Association (AMA) ,2000
- Late renal allograft loss: noncompliance masquerading as chronic rejectionTransplantation Proceedings, 1999
- Causes of Late Renal Allograft Failure in the Ciclosporin EraNephron, 1992
- NONCOMPLIANCE IN ORGAN TRANSPLANT RECIPIENTSTransplantation, 1990